Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Kodiak Sciences Inc. develops innovative retinal therapies using its Antibody Biopolymer Conjugate (ABC) Platform. Its core focus is on creating biologics for major retinal diseases like AMD, diabetic retinopathy, and retinal vein occlusion. The company’s key products include tarcocimab, KSI-501, and KSI-101, targeting inflammation and vascular issues. Kodiak emphasizes high efficacy, durability, and tailored delivery, aiming to improve patient outcomes and reduce treatment burdens in ophthalmology markets.
This description was generated via AI from an annual report. Updated about 1 year ago.